Shiwei, N;
Williams, G;
Jianrong, W;
Junzi, W;
Xueijing, Z;
Hong, Z;
Shude, L;
(2019)
A novel chitosan-based nanomedicine for multi-drug resistant breast cancer therapy.
Chemical Engineering Journal
, 369
pp. 134-149.
10.1016/j.cej.2019.02.201.
Preview |
Text
Shiwei MS - accepted version.pdf - Accepted Version Download (2MB) | Preview |
Abstract
In this study, a novel chitosan-based (CS) nanocarrier was developed for doxorubicin (DOX) and oleanolic acid (OA) co-delivery. CS was first functionalized with folic acid to allow selective uptake by cancer cells, and then subsequently with OA. The resultant copolymer self-assembled into nanoparticles (NPs) upon addition to water. These FA-CS-g-OA@DOX nanoparticles (NPs) had appropriate size (180 nm) and size distribution (PDI < 0.45) for tumor therapy, as well as a high drug-loading efficiency (15.6 % w/w DOX; 5.1% w/w OA) and pH-responsive release properties. In breast cancer MDA-MB-231 cells, more efficient uptake of FA-CS-g-OA@DOX NPs than of free DOX was observed by confocal laser scanning microscopy and flow cytometry. The in vitro cytotoxicity of FA-CS-g-OA@DOX NPs against MDA-MB-231 cells was higher than with free DOX and free OA, while the NPs were less harmful to healthy HUVEC cells. In vivo pharmacokinetic studies showed that FA-CS-g-OA@DOX NPs had a much longer circulation time than free DOX, while biodistribution results revealed that FA-CS-g-OA@DOX could actively target a MDA-MB-231 xenograft tumor in mice. The NPs are found to have apoptosis-enhancing and anti-proliferative capacities in vivo. The presence of OA in the formulation both sensitizes cancer cells to DOX and mitigates DOX-induced damage to healthy tissues. The FA-CS-g-OA@DOX NPs generated in this work hence have great potential for the treatment of multi-drug resistant breast cancers, and further offer a platform to target other cancers.
| Type: | Article |
|---|---|
| Title: | A novel chitosan-based nanomedicine for multi-drug resistant breast cancer therapy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.cej.2019.02.201 |
| Publisher version: | http://doi.org/10.1016/j.cej.2019.02.201 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Chitosan-based nanocarrier; Doxorubicin; Oleanolic acid; Codelivery; Chemosensitizing |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10069538 |
Archive Staff Only
 |
View Item |
